Literature DB >> 29191590

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

Joshua D Lara1, Ann Brunson2, Jonathan W Riess2, Karen Kelly2, Primo N Lara2, David R Gandara3.   

Abstract

BACKGROUND: Small cell lung cancer (SCLC) is an often lethal disease that commonly occurs in older individuals with a history of heavy tobacco use. Limited epidemiologic and outcomes data are available on young SCLC patients aged less than 50 years of age. We assessed clinical variables related to cause specific survival (CSS) of young patients with SCLC.
METHODS: SCLC patients in the California Cancer Registry diagnosed between 1998 and 2012 were included. Primary outcome measure was CSS. Hazard ratios (HR) for CSS were calculated using Cox Proportional Hazards (pH) models for all ages &amp; for patients <50 years, adjusted for baseline variables: age, gender, stage, race, year of diagnosis, initial treatment, socioeconomic status (SES), and location (urban vs. rural).
RESULTS: We identified 22,863 SCLC patients, of which 975 were less than 50 years of age (4.2%). Most patients <50years of age were male (51%), white race (71%), and had stage IV disease (60%). A lower proportion of patients aged 50 years or younger was diagnosed in later years: from 40% in 1998-2002 to 24% in 2008-2012. For all SCLC patients, age less than 50 years was an independent predictor of improved CSS (HR=0.82, p<0.0001). Multivariate Cox pH models showed that in younger patients, female sex (HR=0.81, p=0.0045), Asian race (HR=0.57, p=0.0075), and rural residence (HR=0.75, p=0.042) were associated with better CSS, among other variables.
CONCLUSIONS: In patients with SCLC, age less than 50 years was an independent predictor of improved CSS. Baseline clinical variables associated with better CSS were identified. These results have potential clinical applications.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Lung cancer; Prognostic factors; Registry; Small cell; Young patients

Mesh:

Year:  2017        PMID: 29191590     DOI: 10.1016/j.lungcan.2017.08.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  Characteristics and survival difference of clinical tumor size 0 extensive-stage small cell lung cancer with different metastasis pattern.

Authors:  Haiyong Wang; Xiao Han; Jun Guo; Zhehai Wang
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Socioeconomic Differences and Lung Cancer Survival-Systematic Review and Meta-Analysis.

Authors:  Isabelle Finke; Gundula Behrens; Linda Weisser; Hermann Brenner; Lina Jansen
Journal:  Front Oncol       Date:  2018-11-27       Impact factor: 6.244

3.  Surgery in patients with small cell lung cancer: A period propensity score matching analysis of the Seer database, 2010-2015.

Authors:  Xiaojun Du; Dan Tian; Langbo Liu; Zhongben Tang; Jiarong Xiao; Wen Liu; Shizhang Yuan; Xi Cao; Haiyu Zhou; Jian Zhang
Journal:  Oncol Lett       Date:  2019-09-03       Impact factor: 2.967

4.  Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC.

Authors:  Umit Tapan; Vanessa Fiorini Furtado; Muhammad Mustafa Qureshi; Peter Everett; Kei Suzuki; Kimberley S Mak
Journal:  JTO Clin Res Rep       Date:  2020-10-20

5.  Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival.

Authors:  Umit Tapan; Kimberley S Mak; Michelle H Lee; Muhammad Mustafa Qureshi; Kei Suzuki; Peter Everett
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

6.  Leveraging hybrid biomarkers in clinical endpoint prediction.

Authors:  Maliazurina Saad; Ik Hyun Lee
Journal:  BMC Med Inform Decis Mak       Date:  2020-10-07       Impact factor: 2.796

7.  Sites of Synchronous Distant Metastases, Prognosis, and Nomogram for Small Cell Lung Cancer Patients with Bone Metastasis: A Large Cohort Retrospective Study.

Authors:  Zhiyi Fan; Zhangheng Huang; Yuexin Tong; Zhe Zhu; Xiaohui Huang; He Sun
Journal:  J Oncol       Date:  2021-07-28       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.